ClinicalTrials.gg
Not yet recruitingNCT05761795Updated Nov 16, 2026

Efficacy of IVMED-85 on Pediatric Myopia

A Phase 2 interventional study of IVMED-85 ophthalmic solution, Low Dose and IVMED-85 ophthalmic solution, High dose in Myopia, Progressive, sponsored by iVeena Delivery Systems, Inc.. Not yet recruiting. Open to participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by iVeena Delivery Systems, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
5 Years to 10 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.

The main aims are:

  • Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
  • Assess the safety of a 12-month treatment of IVMED-85

Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.

Read the detailed description

This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.

Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.

Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.

The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.

A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.

02

Conditions studied

  • Myopia, Progressive

Keywords

  • Myopia, Pediatric
03

In context

Myopia, Degenerative

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's planned enrollment of 144 is above the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

iVeena Delivery Systems, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
5 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.

  1. Are 5 to 10 years of age
  2. Have a minimum body weight of 15.45 kg (34 lbs)
  3. Willing and able to provide and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
  4. Willing and able to comply with clinic visits and study-related procedures
  5. Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
  6. Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
  7. Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
  8. Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
  9. Have corneal thickness between 450 and 680 μm
  10. Have IOP ≤22 mmHg
  11. Have axial length ≥20 mm and ≤27 mm
  12. Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
  13. Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    IVMED-85 Low Dose

    Total subjects n=48, IVMED-85 low dose BID for 12 months

    Drug: IVMED-85 ophthalmic solution, Low Dose

  • Experimental
    IVMED-85 High Dose

    Total subjects n=48, IVMED-85 high dose BID for 12 months

    Drug: IVMED-85 ophthalmic solution, High dose

  • Placebo comparator
    Placebo

    Total subjects n=48, placebo BID for 12 months

    Drug: Placebo

Interventions

  • DrugIVMED-85 ophthalmic solution, Low Dose

    Eye drop

  • DrugIVMED-85 ophthalmic solution, High dose

    Eye drop

  • DrugPlacebo

    Eye drop

06

What researchers measure

Primary outcomes

  1. Refractive error change from baseline at Month 12

    Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12

    Time frame: Baseline compared to month 12

Secondary outcomes

  1. Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)

    Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12

    Time frame: From screening to the end of treatment at 12 months

  2. Change in optical biometrics

    Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits

    Time frame: From screening to the end of treatment at 12 months

  3. Refractive error at non-final study visits

    Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12

    Time frame: From screening to the end of treatment at 12 months

  4. Sub foveal choroidal thickness

    Change from baseline in sub foveal choroidal thickness in the SE at Month 12

    Time frame: From screening to the end of treatment at 12 months

  5. Accommodative amplitude in the spherical equivalent

    Change from baseline in accommodative amplitude in the SE at Month 12

    Time frame: From screening to the end of treatment at 12 months

Other outcomes

  1. Progression of high myopia

    Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12

    Time frame: From screening to the end of treatment at 12 months

  2. Progression of prospectively identified progressive myopia

    Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records

    Time frame: From screening to the end of treatment at 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Feb 2029, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Feb 2024 → Feb 2027, primary completion May 2026 → Feb 2029 and completion Dec 2026 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 9, 2023
StartEst.
Feb 2027was Feb 2024
Primary completionEst.
Feb 2029was May 2026
CompletionEst.
Jun 2029was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2024→Feb 2027
Nov 16, 2026
Primary completion
May 2026→Feb 2029
Nov 16, 2026
Study completion
Dec 2026→Jun 2029
Nov 16, 2026
Enrollment
216→144
Nov 16, 2026
Eligibility
Maximum age 16 Years→10 Years; Criteria largely rewritten (36 changes)
What changed in the criteria
  • AddedSubjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
  • AddedAre 5 to 10 years of age
  • AddedHave a minimum body weight of 15.45 kg (34 lbs)
  • AddedWilling and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
  • AddedAble to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
  • AddedWilling and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
  • EditedRefractiveHave refractive error as determined by cycloplegic refraction in both eyesautorefraction: myopia -0.7550 D to -97.750 D (spherical equivalent); astigmatism ≤ 4.00D; anisometropia <3.00 D; anisometropia ≤2.00 D
  • AddedHave BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
  • AddedHave corneal thickness between 450 and 680 μm
  • AddedHave IOP ≤22 mmHg
  • AddedHave axial length ≥20 mm and ≤27 mm
  • AddedWilling to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
  • AddedWilling to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
Inclusion criteria
  • RemovedTo be considered for enrollment in the study, the patient must meet all of the following criteria:
  • RemovedAge 5 to 16 years and 6 months, three age groups cohorts (5-8), (9-12), and (13-16) (Phase 1 patients will be exclusively age 13-16).
  • RemovedBest corrected distance visual acuity better than or equal to Snellen 20/40 (logMAR equivalent 0.3) in both eyes
  • RemovedKmax >40 D and <50 D in both eyes
  • RemovedMinimum corneal thickness > 350 microns in both eyes
  • RemovedAbsence of ocular comorbidities (glaucoma, cataract, anterior segment dysgenesis, corneal scarring, juvenile rheumatoid arthritis, lens subluxation, uveitis, collagen disorders (Ehlers-Danlos, Marfan's syndrome, osteogenesis imperfecta, retinal diseases) in both eyes
  • RemovedWritten informed consent from a parent or legal guardian and assent from participant
Exclusion criteria
  • RemovedA patient who meets any of the following criteria, in either eye, will be excluded from the study:
  • RemovedCurrent or previous myopia treatment with atropine, pirenzepine, or other topical anti-muscarinic
  • RemovedSignificant central corneal scarring or hydrops
  • RemovedKnown copper allergy
  • RemovedUse of rigid gas permeable lenses, including orthokeratology lenses within 90 days of screening
  • RemovedPrevious cornea, glaucoma, eyelid, strabismus (exotropia or esotropia) or intraocular surgeries
  • RemovedPrior history of ocular disorder (e.g., current or prior history of strabismus (exotropia or esotropia), amblyopia, glaucoma, cataract, retinal detachment or nystagmus, or abnormality of the cornea, lens, iris, ciliary body, or central retina)
  • RemovedMyopic degeneration with potential visual acuity worse than Snellen 20/40 (logMAR equivalent 0.3)
  • RemovedIntraocular pressure >26 mmHg
  • RemovedMedical conditions pre-disposing patient to degenerative myopia or abnormal ocular refractive anatomy (e.g., Stickler Syndrome, Down Syndrome, osteogenesis imperfecta, Ehler's-Danlos Syndrome, Retinopathy of Prematurity)
  • RemovedParticipation in a clinical trial with use of any investigational drug or treatment within 30 days prior to Visit 1
  • RemovedEmployees of the study site or their immediate families
  • RemovedPregnancy
  • RemovedHypothyroidism or hyperthyroidism
  • RemovedPatient less than 17 Kg weight
  • RemovedPlanned ophthalmic surgery during the study
Nov 16, 2026
Interventions
Added Drug: IVMED-85 ophthalmic solution, Low Dose·Drug: IVMED-85 ophthalmic solution, High dose; removed Drug: IVMED 85. Arms removed: IVMED-85 Low Dose and placebo·IVMED-85 Mid Dose and placebo·IVMED-85 High Dose and placebo·IVMED-85 Mid Dose
Nov 16, 2026
Primary outcomes
1 added, 7 removed
What changed in the outcomes
  • AddedRefractive error change from baseline at Month 12Time frame: Baseline compared to month 12
  • RemovedPhase 1 Safety - Change in Best corrected distance visual acuityTime frame: Baseline compared to Day 0, Weeks 1, 2 and 4 (+ 5 days)
  • RemovedPhase 1 Safety - Change in Development of corneal scarringTime frame: Baseline compared to Day 0, Weeks 1, 2 and 4 (+ 5 days)
  • RemovedPhase 1 Safety - Change in Patient assessment of comfortTime frame: Baseline compared to Day 0, Weeks 1,2 and 4 (+ 5 days)
  • RemovedPhase 1 Safety - Change in Tyroid enzyme levelsTime frame: Baseline compared to week 4
  • RemovedPhase 1 Safety - Change in Copper serum levelsTime frame: Baseline compared to week 4
  • RemovedPhase 2 Safety - Change in Best corrected distance visual acuityTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
  • RemovedPhase 2 Efficacy - Change/Progression of myopic refractive errorTime frame: Baseline compared to month 12
Nov 16, 2026
Secondary outcomes
7 added, 6 removed
What changed in the outcomes
  • AddedRefractive error (spherical equivalent as determined by cycloplegic manifest refraction)Time frame: From screening to the end of treatment at 12 months
  • AddedChange in optical biometricsTime frame: From screening to the end of treatment at 12 months
  • AddedRefractive error at non-final study visitsTime frame: From screening to the end of treatment at 12 months
  • AddedSub foveal choroidal thicknessTime frame: From screening to the end of treatment at 12 months
  • AddedAccommodative amplitude in the spherical equivalentTime frame: From screening to the end of treatment at 12 months
  • RemovedPhase 2 Safety - Change in Development of corneal scarringTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
  • RemovedPhase 2 Safety - Change in Patient assessment of comfortTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
  • RemovedPhase 2 Efficacy - Change in keratometryTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
  • RemovedPhase 2 Efficacy - Change in Axial lengthTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
  • RemovedPhase 2 Efficacy - Change in Vitreous chamber depthTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
  • RemovedPhase 2 Efficacy - Intermediate change/progression of myopic refractive errorTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9 (+21 days)
  • Addedother outcomeProgression of high myopiaTime frame: From screening to the end of treatment at 12 months
  • Addedother outcomeProgression of prospectively identified progressive myopiaTime frame: From screening to the end of treatment at 12 months
Nov 16, 2026
Contact
Study contact's phone or email changed: s•••@hotmail.com→s•••@iveenamed.com. See the current contact
Nov 16, 2026
Design
Removed Phase 1
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Feb 2024→Feb 2027
    Primary completion May 2026→Feb 2029
    Study completion Dec 2026→Jun 2029
    Enrollment 216→144
    Eligibility Maximum age 16 Years→10 Years; Criteria largely rewritten (36 changes)
    What changed in the criteria
    • AddedSubjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
    • AddedAre 5 to 10 years of age
    • AddedHave a minimum body weight of 15.45 kg (34 lbs)
    • AddedWilling and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
    • AddedAble to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
    • AddedWilling and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
    • EditedRefractiveHave refractive error as determined by cycloplegic refraction in both eyesautorefraction: myopia -0.7550 D to -97.750 D (spherical equivalent); astigmatism ≤ 4.00D; anisometropia <3.00 D; anisometropia ≤2.00 D
    • AddedHave BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
    • AddedHave corneal thickness between 450 and 680 μm
    • AddedHave IOP ≤22 mmHg
    • AddedHave axial length ≥20 mm and ≤27 mm
    • AddedWilling to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
    • AddedWilling to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
    Inclusion criteria
    • RemovedTo be considered for enrollment in the study, the patient must meet all of the following criteria:
    • RemovedAge 5 to 16 years and 6 months, three age groups cohorts (5-8), (9-12), and (13-16) (Phase 1 patients will be exclusively age 13-16).
    • RemovedBest corrected distance visual acuity better than or equal to Snellen 20/40 (logMAR equivalent 0.3) in both eyes
    • RemovedKmax >40 D and <50 D in both eyes
    • RemovedMinimum corneal thickness > 350 microns in both eyes
    • RemovedAbsence of ocular comorbidities (glaucoma, cataract, anterior segment dysgenesis, corneal scarring, juvenile rheumatoid arthritis, lens subluxation, uveitis, collagen disorders (Ehlers-Danlos, Marfan's syndrome, osteogenesis imperfecta, retinal diseases) in both eyes
    • RemovedWritten informed consent from a parent or legal guardian and assent from participant
    Exclusion criteria
    • RemovedA patient who meets any of the following criteria, in either eye, will be excluded from the study:
    • RemovedCurrent or previous myopia treatment with atropine, pirenzepine, or other topical anti-muscarinic
    • RemovedSignificant central corneal scarring or hydrops
    • RemovedKnown copper allergy
    • RemovedUse of rigid gas permeable lenses, including orthokeratology lenses within 90 days of screening
    • RemovedPrevious cornea, glaucoma, eyelid, strabismus (exotropia or esotropia) or intraocular surgeries
    • RemovedPrior history of ocular disorder (e.g., current or prior history of strabismus (exotropia or esotropia), amblyopia, glaucoma, cataract, retinal detachment or nystagmus, or abnormality of the cornea, lens, iris, ciliary body, or central retina)
    • RemovedMyopic degeneration with potential visual acuity worse than Snellen 20/40 (logMAR equivalent 0.3)
    • RemovedIntraocular pressure >26 mmHg
    • RemovedMedical conditions pre-disposing patient to degenerative myopia or abnormal ocular refractive anatomy (e.g., Stickler Syndrome, Down Syndrome, osteogenesis imperfecta, Ehler's-Danlos Syndrome, Retinopathy of Prematurity)
    • RemovedParticipation in a clinical trial with use of any investigational drug or treatment within 30 days prior to Visit 1
    • RemovedEmployees of the study site or their immediate families
    • RemovedPregnancy
    • RemovedHypothyroidism or hyperthyroidism
    • RemovedPatient less than 17 Kg weight
    • RemovedPlanned ophthalmic surgery during the study
    Primary outcomes 1 added, 7 removed
    What changed in the outcomes
    • AddedRefractive error change from baseline at Month 12Time frame: Baseline compared to month 12
    • RemovedPhase 1 Safety - Change in Best corrected distance visual acuityTime frame: Baseline compared to Day 0, Weeks 1, 2 and 4 (+ 5 days)
    • RemovedPhase 1 Safety - Change in Development of corneal scarringTime frame: Baseline compared to Day 0, Weeks 1, 2 and 4 (+ 5 days)
    • RemovedPhase 1 Safety - Change in Patient assessment of comfortTime frame: Baseline compared to Day 0, Weeks 1,2 and 4 (+ 5 days)
    • RemovedPhase 1 Safety - Change in Tyroid enzyme levelsTime frame: Baseline compared to week 4
    • RemovedPhase 1 Safety - Change in Copper serum levelsTime frame: Baseline compared to week 4
    • RemovedPhase 2 Safety - Change in Best corrected distance visual acuityTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
    • RemovedPhase 2 Efficacy - Change/Progression of myopic refractive errorTime frame: Baseline compared to month 12
    Secondary outcomes 7 added, 6 removed
    What changed in the outcomes
    • AddedRefractive error (spherical equivalent as determined by cycloplegic manifest refraction)Time frame: From screening to the end of treatment at 12 months
    • AddedChange in optical biometricsTime frame: From screening to the end of treatment at 12 months
    • AddedRefractive error at non-final study visitsTime frame: From screening to the end of treatment at 12 months
    • AddedSub foveal choroidal thicknessTime frame: From screening to the end of treatment at 12 months
    • AddedAccommodative amplitude in the spherical equivalentTime frame: From screening to the end of treatment at 12 months
    • RemovedPhase 2 Safety - Change in Development of corneal scarringTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
    • RemovedPhase 2 Safety - Change in Patient assessment of comfortTime frame: Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, and 12 (+ 21 days)
    • RemovedPhase 2 Efficacy - Change in keratometryTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
    • RemovedPhase 2 Efficacy - Change in Axial lengthTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
    • RemovedPhase 2 Efficacy - Change in Vitreous chamber depthTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9, 12 (+21 days)
    • RemovedPhase 2 Efficacy - Intermediate change/progression of myopic refractive errorTime frame: Baseline compared to Weeks 1 and 4 (+ 5 days) and Months 3, 6, 9 (+21 days)
    • Addedother outcomeProgression of high myopiaTime frame: From screening to the end of treatment at 12 months
    • Addedother outcomeProgression of prospectively identified progressive myopiaTime frame: From screening to the end of treatment at 12 months
    Interventions Added Drug: IVMED-85 ophthalmic solution, Low Dose·Drug: IVMED-85 ophthalmic solution, High dose; removed Drug: IVMED 85. Arms removed: IVMED-85 Low Dose and placebo·IVMED-85 Mid Dose and placebo·IVMED-85 High Dose and placebo·IVMED-85 Mid Dose
    Design Removed Phase 1
    Contact Study contact's phone or email changed: s•••@hotmail.com→s•••@iveenamed.com. See the current contact
    + 5 other changes: identifiers, verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05761795
Lead sponsor
iVeena Delivery Systems, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Feb 2027 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Sarah Molokhia, RPH, PhD
Contact
smolokhia@iveenamed.com
385-229-4491
Bala Ambati
study chair · iVeena Delivery Systems, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion